drugset / Trial / NCT05868226
PRE-I-SPY Phase I/Ib Oncology Platform Program
Non-randomizedSingle-groupOpen-labelTreatment
Summary
I-SPY Phase I/Ib (I-SPY-P1) is an open-label, multisite platform study designed to evaluate single agents or combinations in a metastatic treatment setting that may be relevant for breast cancer patients with the overall goal of moving promising drug regimens into the I-SPY 2 SMART Design Trial (NCT01042379) and/or other oncology-based trials in a timely manner.
Timeline
- Start
- 2023-02-15
- Primary completion
- 2028-12-30
- Completion
- 2029-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Evorpacept | Protein / enzyme biologic | — | — |
| Subject | Trastuzumab deruxtecan | Monoclonal antibody | — | — |
| Subject | Tucatinib | Small molecule | — | Oral |
| Subject | Zanidatamab | Monoclonal antibody | — | — |